Rexahn Initiates Phase IIa Clinical Trial of Archexin ® in Patients with Metastatic Renal Cell Carcinoma

< p > Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin ® in patients with metastatic renal cell carcinoma (RCC). Archexin was previously granted Orphan Drug Designation for the RCC indication. < /p > < p > 01/15/2014 < /p >
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news